JP2005509622A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509622A5
JP2005509622A5 JP2003535774A JP2003535774A JP2005509622A5 JP 2005509622 A5 JP2005509622 A5 JP 2005509622A5 JP 2003535774 A JP2003535774 A JP 2003535774A JP 2003535774 A JP2003535774 A JP 2003535774A JP 2005509622 A5 JP2005509622 A5 JP 2005509622A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
hydrogen
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509622A (ja
Filing date
Publication date
Priority claimed from GBGB0124928.3A external-priority patent/GB0124928D0/en
Application filed filed Critical
Publication of JP2005509622A publication Critical patent/JP2005509622A/ja
Publication of JP2005509622A5 publication Critical patent/JP2005509622A5/ja
Pending legal-status Critical Current

Links

JP2003535774A 2001-10-17 2002-10-16 5’−カルバモイル−2’−メチル−1,1’−ビフェニル−4−カルボキサミド誘導体及びそのp38キナーゼ阻害薬としての使用 Pending JP2005509622A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124928.3A GB0124928D0 (en) 2001-10-17 2001-10-17 Chemical compounds
PCT/EP2002/011570 WO2003032970A1 (en) 2001-10-17 2002-10-16 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2005509622A JP2005509622A (ja) 2005-04-14
JP2005509622A5 true JP2005509622A5 (enExample) 2006-01-05

Family

ID=9924024

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535774A Pending JP2005509622A (ja) 2001-10-17 2002-10-16 5’−カルバモイル−2’−メチル−1,1’−ビフェニル−4−カルボキサミド誘導体及びそのp38キナーゼ阻害薬としての使用

Country Status (4)

Country Link
EP (1) EP1435933A1 (enExample)
JP (1) JP2005509622A (enExample)
GB (1) GB0124928D0 (enExample)
WO (1) WO2003032970A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
WO2005000298A2 (en) 2003-06-03 2005-01-06 Novartis Ag 5-membered heterocycle-based p-38 inhibitors
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
CN1832928B (zh) 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
DE602004029293D1 (de) 2003-07-25 2010-11-04 Novartis Ag p-38-Kinasehemmer
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
KR20150002863A (ko) * 2004-09-02 2015-01-07 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
AR055271A1 (es) * 2004-10-05 2007-08-15 Smithkline Beecham Corp Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
CA2593550A1 (en) * 2005-01-07 2006-08-10 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
RU2452729C2 (ru) * 2005-09-16 2012-06-10 Арроу Терапьютикс Лимитед Бифенильные производные и их применение при лечении гепатита с
DK1940786T3 (da) * 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
CA2653924A1 (en) * 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
CN101616667A (zh) 2006-10-27 2009-12-30 百时美施贵宝公司 可用作激酶抑制剂的杂环酰胺化合物
ES2560830T3 (es) * 2011-08-31 2016-02-23 Amakem Nv Inhibidores novedosos de ROCK suaves
JP6483146B2 (ja) 2014-02-19 2019-03-13 ハー・ルンドベック・アクチエゼルスカベット アルツハイマー病治療用のbace1阻害剤としての2−アミノ−3,5,5−トリフルオロ−3,4,5,6−テトラヒドロピリジン
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療
HK1253372A1 (zh) 2015-08-12 2019-06-14 H‧隆德贝克有限公司 作为bace1抑制剂的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3,4,5,6-四氢吡啶
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3127373A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
KR102298450B1 (ko) * 2021-01-29 2021-09-08 (주)프레이저테라퓨틱스 p38 MAP 키나아제 억제제로 항염증 활성을 나타내는 신규 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502764A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
ES2384160T3 (es) * 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38

Similar Documents

Publication Publication Date Title
JP2005509622A5 (enExample)
JP2005511532A5 (enExample)
JP2005505618A5 (enExample)
JP2005511531A5 (enExample)
JP2005535586A5 (enExample)
JP2005538100A5 (enExample)
JP2005508960A5 (enExample)
TWI776994B (zh) 經碸吡啶烷基醯胺取代之雜芳基化合物
KR0167395B1 (ko) 부신피질자극호르몬-방출인자 길항제로서의 피라졸로피리미딘
JP2007501831A5 (enExample)
JP2005508967A5 (enExample)
JP2006523193A5 (enExample)
JP2010539110A5 (enExample)
ZA200508158B (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
JP2018525375A5 (enExample)
JP2004517099A5 (enExample)
JP2007538092A5 (enExample)
CA2450922A1 (en) Piperidines for use as orexin receptor antagonists
WO2005047279A8 (en) Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
JP2005508962A5 (enExample)
JP2006523192A5 (enExample)
JP2004525174A5 (enExample)
CN1126472A (zh) 5-ht4受体拮抗物
YU73502A (sh) Farmaceutski aktivni derivati pirolidina
JP2005538111A5 (enExample)